Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 67,048

Document Document Title
WO/2021/057190A1
The present invention relates to quinoline compounds, a preparation method therefor and a use thereof. Specifically, provided are novel quinoline compounds, and pharmaceutically-acceptable salts thereof, a preparation method therefor, an...  
WO/2021/057818A1
Provided in the present invention is a series of selective Factor XIa (FXIa) inhibitors, relating to the technical field of chemical drugs. The present invention also relates to pharmaceutical compositions containing said compounds and a...  
WO/2021/060890A1
The present invention relates to a heteroarylamidopyridinol derivative and a pharmaceutical composition comprising same as an active ingredient for prevention or treatment of an autoimmune disease, specifically, inflammatory bowel diseas...  
WO/2021/053403A1
The invention provides a compound of formula (I) and processes for the manufacture of such compounds, related intermediates, compositions comprising such compounds and the use of such compounds as cytidine triphosphate synthase 1 inhibit...  
WO/2021/054459A1
A benzotriazole compound represented by formula (1). In formula (1), R1 to R4 represent substituents. In formula (1), n1 represents an integer from 0 to 4, and n2 represents an integer from 0 to 3.  
WO/2021/053175A1
The presented invention relates to Omecamtiv mecarbil salts with methane sulfonic acid, benzene sulfonic acid and p-toluene sulfonic acid and to processes for preparation thereof.  
WO/2021/055612A1
The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysos...  
WO/2021/053344A1
There is provided herein a compound of formula I, wherein R1, R2, R3 Y1, Y2, Y3, Y4, R4, R5 and R6 are as defined herein, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung dis...  
WO/2021/053110A1
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...  
WO/2021/053495A1
Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target...  
WO/2021/053161A1
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.  
WO/2021/055630A1
The invention provides substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical...  
WO/2021/055591A1
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, l...  
WO/2021/055295A1
The disclosure provides BRD9 bifunctional compounds of Formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to their preparation, to pharmaceutical compositions comprising them,...  
WO/2021/054421A1
Provided are: a crystal of a 1,3,5-triazine derivative or a solvate thereof; and a method for producing the same. The present invention pertains to a crystal of a compound represented by formula (I) or a solvate thereof, and a pharmace...  
WO/2021/052892A1
The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and R5 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds an...  
WO/2021/055376A1
The disclosure herein provides compounds and pharmaceutical compositions for the modulation of IL-17A useful for the treatment of inflammatory conditions, such as psoriasis.  
WO/2021/053189A1
The presented invention relates to Omecamtiv mecarbil salts, solid forms thereof and to processes for preparation thereof.  
WO/2021/053555A1
Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various ...  
WO/2021/055728A1
Provided are compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein Y, CY, R1, R3, R4, R5 R6 R2a R2b, RMa RMb, and the subscripts m, n, and q are as described herein. The compounds or their pharmaceutically acce...  
WO/2021/053402A2
The invention provides a compound of formula (I) and related aspects.  
WO/2021/055705A1
The present invention provides bisaminoquinoline compounds of Formula (I). The present invention also provides nanocarriers comprising compounds of the present invention, and methods of using the nanocarriers for treating diseases and im...  
WO/2021/048200A1
The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and m...  
WO/2021/048067A1
The present invention relates to a novel non-solvated crystalline form of apalutamide in pure, stable form, and the process for the preparation thereof.  
WO/2021/050612A1
Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral RSV F protein (e.g., Presatovir, MDT 637, JNJ 179, TMC353121, Ziresovir, or an analog thereof) linked to an Fc monomer, an F...  
WO/2021/008588A9
Disclosed are a class of pyrimidine quinoline derivatives comprising prodrugs as well as a preparation method therefor and an application thereof. The structures of the pyrimidine quinoline derivatives are represented by formula (I): R1 ...  
WO/2021/050915A1
The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods ...  
WO/2021/050721A1
Provided herein are compounds, pharmaceutical compositions including such compounds, and methods of using such compounds to treat diseases or disorders associated with MDM2 activity.  
WO/2021/051034A1
Provided herein are RAS protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RAS-me...  
WO/2021/048567A1
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositio...  
WO/2021/047583A1
Disclosed is a tricyclic pyrazole compound shown in formula (I), and a stereoisomer, a pharmaceutically acceptable salt, a solvate, a hydrate, an N-oxide, a prodrug, and a pharmaceutical composition thereof, a preparation method therefor...  
WO/2021/049843A1
The present specification relates to a compound of chemical formula 1 and an organic light emitting device comprising same.  
WO/2021/049522A1
A compound represented by formula (I) or formula (II) has a pest control effect. (In the formulae, Q1 represents a pyrazine ring or the like; G1 represents a nitrogen atom or a carbon atom; X1 represents an alkyl group or the like; m rep...  
WO/2021/050473A1
The present disclosure relates to antimicrobial compositions, particularly to antibiotic compositions; to methods for identification of antimicrobial compositions involving in silico prediction of antimicrobial activity; and to use of an...  
WO/2021/050900A1
Ephrin type receptor tyrosine kinase inhibitors, also known as Eph tyrosine kinase receptor inhibitors, for treating cancer, an inflammatory disease, an autoimmune disease, or a degenerative disease characterized at least in part by the ...  
WO/2021/043966A1
The present invention relates to substituted5-membered nitrogen containing heteroaryl compounds, such as triazole esters, where the heteroaryl ring is further substituted via a linking group such as - NH- with a cyclic group which in tur...  
WO/2021/043077A1
(I) The present invention relates to a substituted pyrazine compound used as an SHP2 phosphatase inhibitor. Specifically, the present invention relates to the compound of formula (I) or a pharmaceutically acceptable salt, an ester, a ste...  
WO/2021/046286A1
A compound of Formula (I) below, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof: (I), in which Ra, Rb, Rc, Rd, X1, X2, R1-R4, W, Z, and L are defined as in the SUMMARY section. Further disclosed are a me...  
WO/2021/045582A1
The present invention provides 2,6-bis-(2-aminopyrimidin-4-yl)pyridin-3-ol dihydrochloride and a pharmaceutical composition comprising same. The 2,6-bis-(2-aminopyrimidin-4-yl)pyridin-3-ol dihydrochloride according to the present inventi...  
WO/2021/046112A1
The invention provides immunoconjugates of Formula (I) comprising an antibody linked by conjugation to one or more aminoquinoline derivatives. The invention also provides aminoquinoline derivative intermediate compositions of Formula (II...  
WO/2021/046447A1
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed com...  
WO/2021/043260A1
A pyrimidine compound, relating more specifically to a pyrimidine compound and a preparation method therefor, and a use thereof in the preparation of a drug. Provided is a compound represented by formula (I), or a tautomer, stereoisomer,...  
WO/2021/046382A1
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed com...  
WO/2021/045159A1
One purpose of the present invention is to provide therapy or prophylaxis of diabetes, obesity, or diabetic complications. The present invention provides: a therapeutic or prophylactic medicine that is for diabetes, obesity, or diabetic ...  
WO/2021/045584A1
The present invention provides 2'-amino-6-(2-amino-6-methylpyrimidine-4-yl)-3'-fluoro-[2,4' -bipyridine]-5-ol dihydrochloride and a pharmaceutical composition comprising same. The 2'-amino-6-(2-amino-6-methylpyrimidine-4-yl)-3'-fluoro-[2...  
WO/2021/045161A1
One aim of the present invention is to treat or prevent chronic kidney disease. Provided is a treatment or prophylactic pharmaceutical composition for chronic kidney disease, that contains an SGLT1-inhibiting compound or a pharmaceutical...  
WO/2021/045460A1
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light emitting device comprising same.  
WO/2021/045585A1
The present invention provides a method for producing a pyrimidinyl bipyridine compound at high yield and high purity without using an expensive silica gel, and an intermediate used for the method.  
WO/2021/046523A1
The present disclosure relates to compounds of Formula (I) as useful materials for OLED's. X1, X2 and X3are N or C(R5) wherein at least one thereof is N; Ar1 and Ar2 are aryl, heteroaryl or cyano; L1 is single bond, arylene or heteroaryl...  
WO/2021/043245A1
A compound represented by general formula (I-a) : has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous syste...  

Matches 151 - 200 out of 67,048